NRIX - Nurix Therapeutics Announces Board Chair Transition | Benzinga
David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles
Current board member Julia P. Gregory unanimously elected new board chair
SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the chair of its board of directors, David L. Lacey, M.D., stepped down as board chair at the conclusion of today's annual meeting of stockholders. The board of directors has unanimously elected board member Julia P. Gregory as its new board chair.
Dr. Lacey, who has served on the Nurix board since 2016, and as board chair since 2019, will remain on the board and will continue to serve as chair of its Compensation Committee and as a member of its Development Advisory Committee.
"Nurix is extremely fortunate to have benefited from David's exceptional guidance as chair over the last five years. His scientific and medical insight has been instrumental in our growth from a private, ligase research company to a public, drug discovery and development company with three innovative programs in clinical development and many drug discovery programs with our collaborators, Gilead, Sanofi and Pfizer," said Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer. "We are excited to have Julia as our new board chair. Her passion, extensive experience and strategic vision will be invaluable as we accelerate development of our drug programs towards regulatory approval and commercialization with the goal of delivering life changing drugs for patients."
"I have been so incredibly impressed with how Nurix has evolved over my tenure as chair. We have literally turned our scientific theories into drugs that are showing great promise for patients in our clinical trials," said Dr. Lacey. "As a member ...